Aquestive Therapeutics Q1 2026: Revenue Surges, Anaphylm Launch Prep

Aquestive Therapeutics Q1 2026 earnings show a 66% revenue surge to $14.4 million, driven by license royalties and manufacturing supply. Net loss narrowed to $8.1 million, with focus on Anaphylm, a sublingual epinephrine film for anaphylaxis. The company had a key FDA meeting, UK regulator chat, and filed a pediatric plan with Europes EMA. They aim for a third quarter resubmission, expecting a six-month review. A $150 million debt deal with Oaktree and RTW funding extension project over $150 million in cash for launch. Analysts grilled them on launch prep, with a 75-person sales force, top-tier patient hubs, and friction-free prescribing planned. AQST-108s Phase 1 safety study cleared with zero adverse events, and business dev talks heat up for Europe, South America, China, and Australia. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1c17af16d701d81a